Join Growin Stock Community!

Barinthus biotherapeutics plcBRNS.US Overview

US StockHealthcare
(No presentation for BRNS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

BRNS AI Insights

BRNS Overall Performance

BRNS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

BRNS Recent Performance

1.01%

Barinthus biotherapeutics plc

0.05%

Avg of Sector

-0.31%

S&P500

BRNS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

BRNS Key Information

BRNS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

BRNS Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. It is advancing a pipeline of product candidates across a range of therapeutic areas, including VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-200, a non-surgical product candidate for persistent high-risk human papillomavirus (HPV); VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer; and VTP-1100, a preclinical cancer candidate designed to utilize the SNAP-CI platform to treat patients with HPV-related cancer. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Harwell, the United Kingdom.

Price of BRNS

BRNS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.25
PB Ratio
0.29
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-463.80%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.86
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
3.25
PB Ratio
0.29
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-463.80%
Revenue Growth (YoY)
-100.00%
Profit Growth (YoY)
-100.00%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
-100.00%

  • When is BRNS's latest earnings report released?

    The most recent financial report for Barinthus biotherapeutics plc (BRNS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating BRNS's short-term business performance and financial health. For the latest updates on BRNS's earnings releases, visit this page regularly.

  • How is BRNS's revenue growth?

    In the latest financial report, Barinthus biotherapeutics plc (BRNS) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does BRNS have?

    As of the end of the reporting period, Barinthus biotherapeutics plc (BRNS) had total debt of 11.57M, with a debt ratio of 0.11. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does BRNS have?

    At the end of the period, Barinthus biotherapeutics plc (BRNS) held Total Cash and Cash Equivalents of 75.67M, accounting for 0.69 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is BRNS's EPS continuing to grow?

    According to the past four quarterly reports, Barinthus biotherapeutics plc (BRNS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.36. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of BRNS?

    Barinthus biotherapeutics plc (BRNS)'s Free Cash Flow (FCF) for the period is -10.28M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 43.89% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of BRNS?

    The latest valuation data shows Barinthus biotherapeutics plc (BRNS) has a Price-To-Earnings (PE) ratio of -0.58 and a Price/Earnings-To-Growth (PEG) ratio of 0.03. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.

BRNS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1